Navigation Links
Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007
Date:11/6/2007

iotensin II, which was dose-dependent and long-lived but reversible with a half-life of about 4 months. Also efficacy was dose-dependent and a significant reduction of the mean ambulatory day-time blood pressure was observed in the group who received the 300 mg dose of the vaccine. Systolic blood pressure (SBP) was reduced by 5.6 mmHg and diastolic blood pressure (DBP) by 2.8 mmHg from baseline.

Furthermore, strong efficacy of the vaccine was observed in the early morning hours, a critical time period when serious cardiovascular events occur frequently. The early morning rise of blood pressure starting at 5 am was significantly reduced by the vaccine, leading at 8 am to a blood pressure difference from baseline of (SBP / DBP) - 25 / - 13 mmHg compared to placebo.

Prof. Juerg Nussberger comments: "Despite the fact that effective drugs are available to treat hypertension, only about one out of four hypertensive patients has the blood pressure successfully controlled. Once people are aware of the often symptomless hypertension, they have to take their medications daily, and many are apparently unable or unwilling to take pills every day for the rest of their lives. The major remaining medical need in this important therapeutic area is thus improved patient compliance. If we could support or substitute the oral therapy with a vaccine that would need to be given just every few months, I think we could achieve a better control of high blood pressure."

Prof. Nussberger adds: "A particularly interesting finding of this study is the excellent control of the blood pressure in the early morning hours achieved by the vaccine. This is a crucial time period when serious events like myocardial infarction and stroke are more likely to occur than during other times of the day. Since currently available drugs often have too short half-lives to affect the rise in early morning blood pressure, this could become a major advantage of the novel vaccine approach. I am loo
'/>"/>

SOURCE Cytos Biotechnology AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Strategic Diagnostics Updates Roth Conference Presentation Time
2. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
3. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
4. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
5. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
9. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
10. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
11. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. George ... Society for Reproductive Medicine (ASRM), a leading professional organization ... In his new role as treasurer, Dr. Hill ... will have a voice in furthering the mission of ... since 1984 when he joined while conducting fellowship training ...
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... leadership to support expansion of the Company,s current and future ... ... 8, 2008 Cylex(TM) has announced,the appointment of Brad L. Stewart ... that develops and manufactures research and in,vitro diagnostic products based on ...
... Match Medicare Policy, SAN CARLOS, Calif., ... and Medicaid Services (CMS) have approved at-home ... policy had mandated that,suspected sleep apnea sufferers ... positive airway pressure (CPAP) treatment for,Medicare patients ...
... Germany, April 8 Sangui BioTech,International, Inc. (OTC: SGBI), ... 30, 2006, on April 3, 2008. According to the ... company almost tripled its sales,of cosmetics and wound management ... yielded sales of approximately USD 137,000 and a Gross,Profit ...
Cached Biology Technology:Cylex Announces Brad L. Stewart as President of the Company 2Medicare Approves in Home Sleep Apnea Testing 2Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses 2Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses 3
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... It may come as a surprise to many that ... they form close relationships with other quails. Nevertheless, it ... environment causes them stress. A group within the UMR ... been studying the influence of adults on the behavioural development ...
... Ore. Researchers at Oregon State University have helped ... groundwork for genetic improvements to related fruits like apples, ... in the journal Nature Genetics . "This ... particularly commercial strawberries," said OSU plant molecular biologist Todd ...
... An international research consortium has sequenced the genome ... in the Dec. 26 advance online edition of the ... to unlock possibilities for breeding tastier, hardier varieties of ... "We,ve created the strawberry parts list," said the consortium,s ...
Cached Biology News:Parents' social problems affect their children -- even in birds 2OSU helps decode strawberry genome in bid to improve fruit 2OSU helps decode strawberry genome in bid to improve fruit 3Georgia Tech team helps decode newly sequenced strawberry genome 2Georgia Tech team helps decode newly sequenced strawberry genome 3
MOUSE ANTI BOVINE TROPONIN I...
Normal donkey serum collected from healthy normal donkeys....
... reagent (F-2902) was developed in collaboration with ... measurement of the kinetics of Fc receptor ... directly in the phagovacuole.2 The Fc OxyBURST ... albumin (BSA) that has been covalently linked ...
Designed for flow cytometric applications intended to identify...
Biology Products: